- All
- Blog
- Grants
- News
- Newsletter
- Publications
- Webinar
Toxys is nominated as one of the top 100 most innovative companies in the Netherlands
Toxys is nominated as one of the top 100 most innovative companies in the Netherlands by the Dutch Chamber of Commerce (KVK). The 2020 KVK Innovatie top 100 nomination recognises our mission to improve animal-free safety testing with novel in vitro assays that offer mechanistic...
Toxys is selected as one of the FD Gazelles of 2020!
Toxys is very proud to announce that we have been selected as one of the FD Gazelles of 2020! The prestigious Gazelle awards are presented by the Dutch Financial Times (Het Financieele Dagblad) to fast-growing and financially successful companies in the Netherlands over the last...
Latest publication about aneugen versus clastogen evaluation and oxidative stress-related MOA
Check out our latest publication "Aneugen versus clastogen evaluation and oxidative stress-related mode-of-action assessment of genotoxic compounds using the ToxTracker reporter assay" published recently in Toxicological Sciences. This paper highlights the extended versions of the ToxTracker assay: ToxTracker ACE and ToxTracker AO. ToxTracker ACE (Aneugen Clastogen...
We are happy to launch ToxPlot: a unique software package for ToxTracker data analysis
We are happy to launch ToxPlot: a unique software package for ToxTracker data analysis. ToxPlot is an ideal add-on for ToxTracker that further increases the value of the assay. ToxPlot allows for extensive data analysis, unbiased data interpretation, automated report generation and secure data storage....
ReproTracker Webinar: introducing our novel in vitro developmental toxicity assay
On the 3rd of September, we hosted a webinar introducing ReproTracker, our novel in vitro developmental toxicity assay. Dr. Giel Hendriks, CEO of Toxys and Sabine Hartvelt, Junior Scientist at Toxys, discussed the challenges in reproductive toxicology and why ReproTracker was developed, along with its...
Toxys appoints Susan Swarte as new non-executive Board member
Leiden, The Netherlands. July 14, 2020 - Toxys BV is a biotech company based in Leiden, The Netherlands, that provides innovative in vitro toxicity screening solutions to identify carcinogenic and other hazardous properties of compounds for the pharmaceutical, chemical, cosmetics and food industry. Today, Toxys...
Webinar: A highly quantitative in vitro method for mechanistic genotoxicity screening
On the 12th of May our recorded webinar with our partners at Miltenyi Biotech, introducing our in vitro genotoxicity assay, ToxTracker®, its opportunities, advantages and challenges faced when using this assay for mechanistic toxicity testing, was released. We also highlight the potential of using reliable flow...
Toxys signs agreement with BioPartner Leiden for new laboratory
Leiden, The Netherlands. May 5, 2020 - Toxys is an innovative Dutch biotech company that develops unique animal-free laboratory tests for the safety assessment of novel medicines, chemicals, cosmetics and food. Today, Toxyssigned an agreement with BioPartner Leiden for its new laboratory facilities. In spring...
ToxTracker webinar with user applications now available!
On the 18th of March our webinar on ToxTracker, including use applications for the Fragrance and Flavour industry and Agro-Chemical industry has been held. During this webinar, our new assays, ReproTracker and TubulinTracker, were also launched. The webinar can be found at our dedicated website for all...
COVID19 Contingency Planning and Continuity of Project Delivery from Toxys
Toxys has been monitoring the global corona virus outbreak since the beginning of this year and is updating business continuity plans daily. We want to assure you that we remain dedicated to provide high quality services to our clients while also protecting the health of...
Toxys raises €2 million financing for global expansion of its unique animal-free chemical safety tests
Leiden, The Netherlands. March. 10, 2020 - Toxys is an innovative Dutch biotech company that develops unique animal-free laboratory tests for the safety assessment of novel medicines, chemicals, cosmetics and food. Today, Toxys announces a €2 million funding round from KIKK Capital, InnovationQuarter, Zeeland Investment...
Save the date: Altertox/Toxys workshop Novel in vitro methods and AOP approaches in genetic toxicology
Hands-on workshop: Novel in vitro methods and AOP approaches in genetic toxicology. By: Altertox/Toxys When: 7-8 July 2020 Where: Leiden, The Netherlands Program will be available soon, please contact us for any questions. ...
ToxTracker event and launch party at SOT 2020
You are cordially invited to join the ToxTracker event and launch party during the SOT 2020 meeting in Anaheim. During this event we will launch new assays, software and the ToxTracker Academy. We will also update you on the latest developments around ToxTracker and its...
Toxys strengthens leadership team with appointment of CBO and COO positions
Leiden, The Netherlands. Jan. 21, 2020 - Today, Toxys announces the appointment of a Chief Business Officer (CBO) and a Chief Operating Officer (COO). Toxys BV is a biotech company based in Leiden, The Netherlands, that provides innovative, high-fidelity in vitro toxicity screening solutions to identify carcinogenic and other hazardous properties...
ToxTracker for regulatory applications
We are frequently asked whether ToxTracker data have ever been included in safety dossiers to the regulatory authorities. The answer is yes, but often this information is not publicly available. And in many cases we simply don’t know. But now there is an example available...
Winner of UKEMS Young Scientist Poster Award
We are very proud that our scientist Inger Brandsma won the UKEMS Young Scientist Poster Award for her poster ‘Extension of the ToxTracker reporter assay for classification of compounds with a clastogenic or aneugenic mode of action’ at BTS-UKEMS Congress 2019. ToxTracker ACE (Aneugen Clastogen Evaluation)...
Toxys Newsletter February 2019
Here you can view our newsletter from February 2019...
